Diabetic retinal disease cure accelerator: Modernizing staging and endpoints.

Konstantina Sampani¹, Ward Fickweiler², Dorene S Markel³, Latrice Faulkner³, Stela Vujosevic⁴, Tunde Peto⁵, Olivia Meyerhoffer⁶, Malvina Eydelman⁷, S Robert Levine³, Jennifer K Sun², Thomas W Gardner⁸, Michael D Abramoff⁹

¹Beetham Eye Institute, Joslin Diabetes Center, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

²Beetham Eye Institute, Joslin Diabetes Center, Boston, MA, USA; Department of Ophthalmology, Harvard Medical School, Boston, MA, USA.

³Mary Tyler Moore Vision Initiative, Greenwich, CT, USA.

⁴Department of Biomedical, Surgical and Dental Sciences, University of Milan, Italy; Eye Clinic, IRCCS MultiMedica, Milan, Italy.

⁵School of Medicine, Dentistry and Biomedical Sciences, Queen's University, Belfast, Ireland.

⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany.

⁷Collaborative Community on Ophthalmic Innovation (CCOI), USA.

⁸Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan Medical School, Ann Arbor, MI, USA.

⁹Department of Ophthalmology and Visual Sciences, The University of Iowa, Iowa City, IA, USA; Iowa City VA Medical Center, Iowa City, IA, USA; Department of Biomedical Engineering, The University of Iowa, Iowa City, IA, USA; Department of Electrical and Computer Engineering, The University of Iowa, Iowa City, IA, USA; Digital Diagnostics Inc, Coralville, IA, USA. Electronic address: michael-abramoff@uiowa.edu.

PubMed DOI

Abstract

The "Diabetic Retinal Disease (DRD) Cure Accelerator," a joint initiative by the Mary Tyler Moore Vision Initiative and the Collaborative Community on Ophthalmic Innovation, aims to modernize clinically meaningful staging systems and endpoints for DRD. During a June 2025 workshop involving over 100 international experts, participants emphasized the urgent need for validated structural and function…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.